ASX:MSB

Email Alerts for:
ASX:MSB

Mesoblast draws down $15m of capital to accelerate product commercialisation programs

14 Jan 2019 - Mesoblast (ASX:MSB) has today announced it has drawn down (a further) $15 million from its US$75 million four-year credit facility with Hercules Capital.

Healius shares dip after rejecting takeover offer: ASX is 1.5% higher at noon

07 Jan 2019 - The ASX has continued to rise throughout this morning after the US posted solid gains on Friday after a boost from impressive employment data from all jobs except far…

Christmas holiday week ends on the up: ASX closes 1.02% higher

28 Dec 2018 - It has been a positive day of trade for the Australian share market as the market closed in positive territory. Most of this week's gains came on Thursday. The big fo…

Mesoblast pipeline growth in regenerative medicine industry

28 Dec 2018 - Mesoblast (ASX:MSB) today released their corporate review showing how the company will enter 2019 with the most mature cell therapy product pipeline and technology pl…

Santa sleigh leads ASX lower: Aus shares 0.2% lower at noon

19 Dec 2018 - Mid-session report. ASX continues to slide on oil slipping further amid less oil demand. Inghams Group's (ASX:ING) Joel Thickins to retire, its shares trade 26% highe…

US stocks rise on trade hopes: ASX poised to open higher

16 Nov 2018 - The ASX is set to open higher amid optimism that China and the US are seeking to resolve their trade spat. Wall St had a rollercoaster of a day. US stocks rose for th…

Mesoblast join with Tasly for China deal

12 Oct 2018 - Regenerative medicine comapny Mesoblast (ASX:MSB) today announced completion of the transaction with Tasly Pharmaceutical Group to establish a strategic partnership i…

Rates to hold for 25th time: ASX slips 0.5% at noon, back to June levels

02 Oct 2018 - Market at Midday. ASX200 wipes out 3 months of gains and takes the market back to June levels. Rates to hold for 25th time. Most sectors lower. Mesoblast down 9.4% de…

Mesoblast (ASX:MSB) Presentation, FNN Investor Event, August 2018, Sydney

22 Aug 2018 - Mesoblast Limited (ASX:MSB) Head of Business Development and Licensing, David Oxley, presents details about the company's Phase 3 trials, its agreement with Tasly Chi…

Mesoblast (ASX:MSB) talks disruptive cellular medicines

22 Aug 2018 - Mesoblast Limited (ASX:MSB) Head, Business Development and Licensing, David Oxley, discusses the company's Phase 3 trials, its agreement with Tasly China and the near…

ANZ shares have further to run

23 Jul 2018 - Fairmont Equities managing director Michael Gable takes a technical look at Australia and New Zealand Banking Group (ASX:ANZ), the ASX200, Doray Minerals (ASX:DRM), T…

Nasdaq hits record high: Aus shares set to rise

18 Jul 2018 - Australian shares are set to lift at the open, bolstered by gains on Wall Street overnight. Mesoblast (ASX:MSB) has inked a deal with Tasly Pharmaceutical Group.

Mesoblast appoints Shawn Cline Tomasello to Board

11 Jul 2018 - Cellular medicine company, Mesoblast (ASX:MSB) has announced that Shawn Cline Tomasello has joined its Board of Directors.

China tariff stress: Aus shares 0.3% higher at noon

19 Jun 2018 - The Australian share market has seen its strong advance falter after President Trump’s threat of new tariffs on China. It is still sitting above yesterday's close des…

Mesoblast bigger revenues, loss drops and hires new CFO

31 May 2018 - Mesoblast (ASX:MSB) reports after tax loss of US$14.5 million in the nine months to 31 March 2018, an improvement of 71 per cent. It also bumps up revenue and R&D spe…

Lithium shines again: Aus shares close 0.16% higher

29 May 2018 - Market Wrap. ASX claws back some of yesterdays loses. Lithium players charged ahead today with Galaxy Resources (ASX:GXY) and Orocobre (ASX:ORE) taking the first and …

Mesoblast & Cartherics to develop off the shelf cancer treatment

29 May 2018 - Cellular medicine company, Mesoblast (ASX:MSB) has partnered with Cartherics to develop an off the shelf treatment for solid cancer.

10-year highs: Aus shares 0.4% higher at noon

08 May 2018 - Market at Midday: ASX200 back at 10-year highs. Retail trade remained steady in March in seasonally adjusted terms, disappointing economists who expected a rise of 0.…

Mesoblast desire for product entry to be accelerated

18 Apr 2018 - Mesoblast Limited (ASX:MSB; Nasdaq:MESO) is looking to accelerate their entry for product MPC-150-IM into the cardiovascular market after an successful set of on-goin…

Be careful with these stocks

16 Apr 2018 - Fairmont Equities managing director Michael Gable takes a technical look at Galaxy Resources, Afterpay Touch Group, Woodside Petroleum and Mesoblast.

Mesoblast enters in $75m credit facility with Hercules Capital

07 Mar 2018 - Regenerative medical company Mesoblast (ASX:MSB) has entered into a $75 million non-dilutive four year credit facility with Hercules Capital.

Expect more upside for Mesoblast

05 Mar 2018 - Fairmont Equities managing director Michael Gable takes a technical look at Mesoblast, Xero, BHP Billiton, Twitter Inc, Nearmap and Wesfarmers.

A large rally is beginning for Sandfire

26 Feb 2018 - Fairmont Equities managing director Michael Gable takes a technical look at Sandfire Resources NL (ASX:SFR), Mesoblast (ASX:MSB), Genworth Mortgage Insurance Australi…

Bumpy sleigh ride: Aus shares 0.1% lower at noon

21 Dec 2017 - Market at Midday: 60 per cent of the sectors trading below the line at noon. Property taking biggest hit after Charter Hall Group (ASX:CHC) fell 2.6 per cent. Treasur…

Mesoblast grants TiGenix global patent license

15 Dec 2017 - Developer of innovative cell-based medicines Mesoblast (ASX:MSB) grants biopharmaceutical company TiGenix an exclusive global patent license that enables the global c…